Caris Life Sciences Inc
CAI
NASDAQ
Biotechnology
$21.80
USD
-0.38 (-1.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.27B
Volume 3.9M
About Caris Life Sciences Inc
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. The company is headquartered in Irving, Texas and currently employs 1,846 full-time employees. The company went IPO on 2025-06-18. The firm develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
CEO
Mr. David Halbert
HQ
Irving, TEXAS, US
Founded
2025
Employees
1,846
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
5 metrics our research team weighs before forming a view on CAI.
Based on Quantli research · SEC filings · as of Q2 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Gross Margin (TTM)
69.7%
—
Operating Margin (TTM)
15.5%
—
Net Margin (TTM)
10.6%
—
ROE (TTM)
17.8%
—
Free Cash Flow (TTM)
$123.96M
—
Financial Snapshot
Revenue
$989.61M
— YoY
Gross Margin
70%
TTM
— YoY
Net Income
$105.14M
— YoY
Operating Cash Flow
$168.56M
— YoY
Key Statistics
Open
$22.26
Previous Close
$22.18
Day Range
$21.45 - $22.43
52 Week Range
$14.19 - $42.50
Volume
3.9M
Average Volume (10 Days)
6.0M
Dividend Yield
—
Valuation Measurement
Market Cap
$6.27B
P/E Ratio (TTM)
59.62
P/S Ratio (TTM)
6.33
Price / Book
10.59
Financial Highlights
Profit Margin
10.6%
Return on Assets
8.6%
Return on Equity
17.8%
Revenue (TTM)
$989.61M
Net Income (TTM)
$105.14M
Diluted EPS (TTM)
$0.38
Total Cash (MRQ)
$690.91M
Levered FCF (TTM)
$123.96M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
TVTX
Travere Therapeutics Inc
$62.14
▲ +1.2%
ACAD
ACADIA Pharmaceuticals Inc
$28.24
▼ -0.5%
SRRK
Scholar Rock Holding Corp
$52.52
▼ -1.0%
MIRM
Mirum Pharmaceuticals Inc
$100.64
▲ +1.9%
ERAS
Erasca Inc
$18.38
▲ +2.9%
DYN
Dyne Therapeutics, Inc
$25.70
▼ -1.0%
PTCT
PTC Therapeutics Inc
$71.70
▼ -0.4%
COGT
Cogent Biosciences Inc
$37.93
▲ +1.7%
DNTH
Dianthus Therapeutics Inc
$115.96
▲ +5.8%
Earnings Calendar
Next Earnings
Estimated Q3 Release
Nov 03
Est. EPS
Adjusted consensus estimate
$0.04
Analyst Consensus
Based on 1 analyst ratings
Avg Target: $32.00
(+46.8% upside)
High: $32.00 · Low: $32.00
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%